The company focuses on targeting critical receptors on the surface of both innate and adaptive immune cells, aiming to manipulate the immune system in a dual manner. By leveraging a family of receptors that regulate innate and adaptive immunity across various cell types, such as macrophages, dendritic cells, natural killer cells, and T-cells, Adanate aims to offer a unique treatment strategy for improved cancer control. Their technology holds promise for a novel therapy method that could potentially revolutionize cancer treatment.